Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GNLB raised $23.7 million in a registered direct offering of 12.9 million units at $1.84 per
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury